TG Therapeutics Inc (NASDAQ:TGTX) Shares Bought by Bank of New York Mellon Corp

Bank of New York Mellon Corp lifted its stake in TG Therapeutics Inc (NASDAQ:TGTX) by 10.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 311,004 shares of the biopharmaceutical company’s stock after buying an additional 29,627 shares during the period. Bank of New York Mellon Corp owned approximately 0.35% of TG Therapeutics worth $2,690,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Raymond James & Associates lifted its stake in shares of TG Therapeutics by 15.6% in the 1st quarter. Raymond James & Associates now owns 381,437 shares of the biopharmaceutical company’s stock worth $3,067,000 after acquiring an additional 51,418 shares during the period. Edge Wealth Management LLC acquired a new stake in shares of TG Therapeutics in the 2nd quarter worth $270,000. SG Americas Securities LLC lifted its stake in shares of TG Therapeutics by 5.0% in the 2nd quarter. SG Americas Securities LLC now owns 30,858 shares of the biopharmaceutical company’s stock worth $267,000 after acquiring an additional 1,481 shares during the period. Aperio Group LLC acquired a new stake in shares of TG Therapeutics in the 2nd quarter worth $32,000. Finally, Cutter & CO Brokerage Inc. acquired a new stake in shares of TG Therapeutics in the 2nd quarter worth $176,000. 52.96% of the stock is currently owned by hedge funds and other institutional investors.

Several analysts recently commented on the stock. Zacks Investment Research upgraded shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 15th. BidaskClub cut shares of TG Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, September 21st. Finally, ValuEngine upgraded shares of TG Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $11.90.

NASDAQ:TGTX traded up $0.02 during mid-day trading on Friday, hitting $5.20. 688,061 shares of the company’s stock traded hands, compared to its average volume of 1,199,059. The company has a debt-to-equity ratio of 2.77, a quick ratio of 1.69 and a current ratio of 1.69. The firm’s 50 day simple moving average is $5.98 and its 200 day simple moving average is $7.16. TG Therapeutics Inc has a 1 year low of $3.32 and a 1 year high of $9.38.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Friday, August 9th. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.43) by $0.01. The firm had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.04 million. TG Therapeutics had a negative net margin of 99,488.13% and a negative return on equity of 496.99%. As a group, research analysts expect that TG Therapeutics Inc will post -1.52 earnings per share for the current fiscal year.

About TG Therapeutics

TG Therapeutics, Inc, a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing.

Featured Article: What moving averages are used to define a golden cross?

Institutional Ownership by Quarter for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.